

Application No. 10/756,778 – Amendment filed July 23, 2007  
Office Action dated January 24, 2007

**AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace prior versions and listings of claims in the application:

Claim 3 and 16-18 were amended. Claims 1-2, 4-15 and 19-21 are cancelled. Underlines indicate insertions and ~~strikethrough~~ indicate deletions. Claim 23 is new.

**Listing of claims:**

Claims 1-2. (Cancelled)

Claim 3. (Currently amended) An isolated Cry31Aa polypeptide having cytotoxic activity against human cancer cells selected from the group consisting of Hela, Sawano, TCS, MOLT-4, HL-60, Jurkat, A549, Hep-G2 and Caco-2 cells, the polypeptide comprising a sequence having at least 97% identity with the amino acid sequence of SEQ ID NO: 8.

Claims 4-15.(Cancelled)

Claim 16. (Currently amended) An isolated Cry31Aa polypeptide having cytotoxic activity against human cancer cells selected from the group consisting of Hela, Sawano, TCS, MOLT-4, HL-60, Jurkat, A549, Hep-G2 and Caco-2 cells, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 13, with the proviso that the polypeptide does not comprise amino acids 232 to 723 of SEQ ID NO: 18.

Claim 17. (Currently amended) The isolated polypeptide of claim 16, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 15.

Application No. 10/756,778 – Amendment filed July 23, 2007  
Office Action dated January 24, 2007

Claim 18. (Currently amended) The isolated polypeptide of claim 3, wherein said polypeptide comprises the amino acid sequence of SEQ ID NO: 8.

Claims 19-22. (cancelled)

Claim 23. (New). The isolated polypeptide of claim 3, wherein said polypeptide consists of the amino acid sequence of SEQ ID NO: 8.